Altogether, this suggests that the CHEK2 1100delC-associated signature of 188 genes is distinct from other signatures specifically built to predict breast cancer survival or classify tumors into subtypes and reflects the downstream effects of the germline CHEK2 1100delC mutation on tumor progression. This evidence concerns the gene CHEK2 and neoplasm.